<DOC>
	<DOCNO>NCT01285466</DOCNO>
	<brief_summary>The purpose trial determine maximum tolerate dose ( MTD ) BEZ235 BKM120 combination weekly paclitaxel weekly paclitaxel/trastuzumab .</brief_summary>
	<brief_title>A Trial Oral BEZ235 BKM120 Combination With Paclitaxel With Without Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient metastatic locally advanced solid tumor , weekly paclitaxel treatment indicate ( BEZ235paclitaxel /BKM120paclitaxel treatment ) HER2+ metastatic locally advanced breast cancer patient eligible weekly paclitaxel trastuzumab ( BEZ235paclitaxeltrastuzumab /BKM120paclitaxeltrastuzumab treatment ) Adult patient ( ≥ 18 year ) ( male , female ) World Health Organization ( WHO ) performance status ≤ 2 Adequate bone marrow function : Adequate hepatic renal function : Patients primary central nervous system ( CNS ) tumor CNS tumor involvement . However , patient metastatic CNS lesion may participate trial , patient &gt; 4 week therapy ( include radiation and/or surgery ) completion , clinically stable respect tumor time study entry , receive enzymeinducing antiepileptic drug corticosteroid therapy taper , treatment brain metastases Patients receive prior systemic anticancer therapy within follow time frame Cyclical chemotherapy : ≤ 3 week study treatment ( 6 week patient treat nitrosoureas ) Biological therapy : ≤ 4 week study treatment , except treatment trastuzumab ( part trial ) Investigational drug : ≤ 4 week study treatment Patients undergone major surgery ≤ 4 week study treatment Patients receive chronic treatment corticosteroid immunosuppressive agent Patients uncontrolled , unmanageable , treatmentrefractory diabetes mellitus Active history major depressive episode , bipolar disorder , obsessivecompulsive disorder , schizophrenia , history suicide attempt ideation , homicide , judge investigator and/or base recent psychiatric assessment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>BEZ235</keyword>
	<keyword>BKM120</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>trastuzumab</keyword>
</DOC>